The influence of vitamin d deficiency on cancers and autoimmune diseases development;Wplyw niedoboru witaminy D na rozwój nowotworów i chorób autoimmunologicznych

Endokrynologia Polska

Volumn 58, Issue 2, 2007, Pages 140-152

  Kurylowicz, Alina ^a   Bednarczuk, Tomasz ^a   Nauman, Janusz ^a  

^a POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

Autoimmune diseases; Cancer; Vitamin D

Indexed keywords

CALCITRIOL; COLECALCIFEROL; DRUG DERIVATIVE; VITAMIN D;

ANIMAL; AUTOIMMUNE DISEASE; BONE DISEASE; BREAST TUMOR; CALCIUM INTAKE; COMORBIDITY; EPIDEMIOLOGY; HUMAN; LEUKEMIA; METABOLISM; MOUSE; OSTEOPOROSIS; PHOTOTHERAPY; REVIEW; SEASON; STATISTICS; SUNLIGHT; VITAMIN D DEFICIENCY;

ANIMALS; AUTOIMMUNE DISEASES; BONE DISEASES; BREAST NEOPLASMS; CALCITRIOL; CALCIUM, DIETARY; CAUSALITY; CHOLECALCIFEROL; COMORBIDITY; HUMANS; LEUKEMIA; MICE; OSTEOPOROSIS; SEASONS; SUNLIGHT; ULTRAVIOLET THERAPY; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 39049130323     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Walters MR. Newly identified actions of the vitamin D endocrine system. Endocr Rev 1992; 13: 719-764.
2. Prosser E, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 2004; 29: 664-673.
3. St-Arnaud R, Glorieux FH. 24,25-Dihydroxyvitamin D-active metabolite or inactive catabolite? Endocrinology 1998; 139: 3371-3374.
4. White P, Cooke N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metab 2000; 11: 320-327.
5. Gniadecki R. Nongenomic signaling by vitamin D: a new face of Src. Biochem Pharmacol 1998; 56: 1273-1277.
6. Puzianowska-Kuznicka M, Pietrzak M, Turowska O i wsp. Thyroid hormones and their receptors in the regulation of cell proliferation. Acta Biochim Pol 2006; 53: 641-650.
7. Tanaka H, Abe E, Miyaura C i wsp. 1 alpha,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60). Biochem J 1982; 204: 713-719.
8. Colston K, Colston MJ, Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 1981; 108: 1083-108-6.
9. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80: 1678-8168.
10. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132 (5): 1952-1960.
11. Zhuang SH, Burnstein KL. Antiproliferative effect of 1alpha, 25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998; 139: 1197-1207.
12. Liu M, Lee MH, Cohen M i wsp. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996; 10: 142-153.
13. Wade WN, Willingham MC, Koumenis C i wsp. p27Kip1 is essential for the antiproliferative action of 1,25-dihydroxyvitamin D3 in primary, but not immortalized, mouse embryonic fibroblasts. J Biol Chem 2002; 277: 37 301-37 30-6.
14. Verlinden L, Eelen G, Van Hellemont R i wsp. 1 alpha, 25-Dihydroxyvitamin D(3)-induced down-regulation of the checkpoint proteins, Chk1 and Claspin, is mediated by the pocket proteins p107 and p130. J Steroid Biochem Mol Biol 2007 (w druku).
15. Desprez PY, Poujol D, Falette N i wsp. 1,25-Dihydroxyvitamin D3 increases epidermal growth factor receptor gene expression in BT-20 breast carcinoma cells. Biochem Biophys Res Commun 1991; 176: 1-6.
16. Bouillon R, Eelen G, Verlinden L i wsp. Vitamin D and cancer. J Steroid Biochem Mol Biol 2006; 102: 156-162.
17. Moreno J, Krishnan AV, Peehl DM i wsp. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res 2006; 26: 2525-2530.
18. Beer TM, Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. Mol Cancer Ther 2004; 3: 373-381.
19. Elstner E, Linker-Israeli M, Said J i wsp. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 1995; 55: 2822-2830.
20. Xu HM, Tepper CG, Jones JB i wsp. 1,25-Dihydroxyvitamin D3 protects HL60 cells against apoptosis but down-regulates the expression of the bcl-2 gene. Exp Cell Res 1993; 209: 367-374.
21. Flanagan L, Packman K, Juba B i wsp. Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J Steroid Biochem Mol Biol 2003; 84: 181-192.
22. Hansen CM, Frandsen TL, Brunner N i wsp. 1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 1994; 12: 195-202.
23. Konety BR, Lavelle JP, Pirtskalaishvili G i wsp. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol 2001; 165: 253-258.
24. Young MR, Ihm J, Lozano Y i wsp. Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother 1995; 41: 37-46.
25. Bao BY, Yao J, Lee YF. 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 2006; 27: 1883-1893.
26. Reichrath J, Kamradt J, Zhu XH i wsp. Analysis of 1,25-dihydroxyvitamin D(3) receptors (VDR) in basal cell carcinomas. Am J Pathol 1999; 155: 583-589.
27. Reichrath J, Rafi L, Muller SM i wsp. Immunohistochemical analysis of 1,25-dihydroxyvitamin D3 receptor in cervical carcinoma. Histochem J 1998; 30: 561-567.
28. Buras RR, Schumaker LM, Davoodi F i wsp. Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat 1994; 31: 191-202.
29. Madej A, Puzianowska-Kuznicka M, Tanski Z i wsp. Vitamin D receptor binding to DNA is altered without the change in its expression in human renal clear cell cancer. Nephron Exp Nephrol 2003; 93: 150-157.
30. Nejentsev S, Godfrey L, Snook H i wsp. Comparative highresolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene. Hum Mol Genet 2004; 13: 1633-1639.
31. Carling T, Rastad J, Akerstrom G i wsp. Vitamin D receptor (VDR) and parathyroid hormone messenger ribonucleic acid levels correspond to polymorphic VDR alleles in human parathyroid tumors. J Clin Endocrinol Metab 1998; 83: 2255.-2259.
32. Graafmans WC, Lips P, Ooms ME i wsp. The effect of vitamin D SUPPL.ementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype. J Bone Miner Res 1997; 12: 1241-1246
33. Marc J, Prezelj J, Komel R i wsp. VDR genotype and response to etidronate therapy in late postmenopausal women. Osteoporos Int 1999; 10: 303-306
34. Morrison NA, Qi JC, Tokita A i wsp. Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367: 284-287.
35. Chen WY, Bertone-Johnson ER, Hunter DJ i wsp. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 2335-2339.
36. John EM, Schwartz GG, Koo J i wsp. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res 2005; 65: 5470-5479.
37. Albertson DG, Ylstra B, Segraves R i wsp. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000; 25: 144-14-6.
38. Solomon C, Kremer R, White JH i wsp. Vitamin D resistance in RAS-transformed keratinocytes: mechanism and reversal strategies. Radiat Res 2001; 155: 156-162.
39. Khanim FL, Gommersall LM, Wood VH. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene 2004; 23: 6712-6726.
40. Grant WB, Garland CF. The association of solar ultraviolet B (UVB) with reducing risk of cancer: multifactorial ecologic analysis of geographic variation in age-adjusted cancer mortality rates. Anticancer Res 2006; 26: 2687-2699.
41. Ahonen MH, Tenkanen L, Teppo L i wsp. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000; 11: 847-852.
42. Garland CF, Comstock GW, Garland FC i wsp. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989; 2: 1176-1178.
43. Tangpricha V, Spina C, Yao M i wsp. Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice. J Nutr 2005; 135: 2350-2354.
44. Welsh J. Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr 2004; 80: 1721-1724.
45. Grant WB, Garland CF, Holick MF. Comparisons of estimated economic burdens due to insufficient solar ultraviolet irradiance and vitamin D and excess solar UV irradiance for the United States. Photochem Photobiol 2005; 81: 1276-128-6.
46. Grant WB. Ecologic studies of solar UV-B radiation and cancer mortality rates. Recent Results Cancer Res 2003; 164: 371-377.
47. Robsahm TE, Tretli S, Dahlback A i wsp. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 2004; 15: 149-158.
48. Zhou W, Suk R, Liu G i wsp. Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2005; 14: 2303-2309.
49. Dunlap N, Schwartz GG, Eads D i wsp. 1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha, 25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. Br J Cancer 2003; 89: 746-753.
50. Polar MK, Gennings C, Park M i wsp. Effect of the vitamin D3 analog ILX 23-7553 on apoptosis and sensitivity to fractionated radiation in breast tumor cells and normal human fibroblasts. Cancer Chemother Pharmacol 2003; 51: 415-421.
51. Gross C, Stamey T, Hancock S i wsp. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) J Urol 1998; 159: 2035-2039.
52. Beer TM, Eilers KM, Garzotto M i wsp. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003; 21: 123-128.
53. Johnson CS, Hershberger PA, Bernardi RJ i wsp. Vitamin D receptor: a potential target for intervention. Urology 2002; 60: 123-130.
54. Bower M, Colston KW, Stein RC i wsp. Topical calcipotriol treatment in advanced breast cancer. Lancet 1991; 337: 701-702.
55. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109-1118.
56. Penna G, Adorini L. 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405-2411.
57. Cella M, Engering A, Pinet V i wsp. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 1997; 388: 782-787.
58. Caux C, Massacrier C, Vanbervliet B i wsp. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994; 180: 1263-1272.
59. Towers TL, Staeva TP, Freedman LP. A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte- macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun. Mol Cell Biol 1999; 19: 4191-4199.
60. D.Ambrosio D, Cippitelli M, Cocciolo i wsp. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NFkappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998; 101: 252-262.
61. Gregori S, Casorati M, Amuchastegui S i wsp. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001; 167: 1945-1953.
62. Bhalla AK, Amento EP, Serog B i wsp. H-1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol 1984; 133: 1748-1754.
63. Reichel H, Koeffler HP, Tobler A i wsp. 1 alpha,25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci U S A 1987; 84: 3385-3389.
64. Rigby WF, Denome S, Fanger MW. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest 1987; 79: 1659-1664.
65. Boonstra A, Barrat FJ, Crain C i wsp. 1alpha,25-Dihydroxyvitamin D3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001; 167: 4974-4980.
66. Staeva-Vieira TP, Freedman LP-1,25-dihydroxyvitamin D3 inhibits IFN-gamma and IL-4 levels during in vitro polarization of primary murine CD4+ T cells. J Immunol 2002; 168: 1181.-1189.
67. Willheim M, Thien R, Schrattbauer i wsp. Regulatory effects of 1alpha,25-dihydroxyvitamin D3 on the cytokine production of human peripheral blood lymphocytes. J Clin Endocrinol Metab 1999; 84: 3739-3744.
68. Alroy I, Towers TL, Freedman LP. Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol 1995; 15: 5789-5799.
69. Cippitelli M, Santoni A. Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol 1998; 28: 3017-3030.
70. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001; 345: 340-350.
71. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996; 93: 7861-7864.
72. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998; 128: 68-72.
73. Mathieu C, Waer M, Laureys J i wsp. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 1994; 37: 552-558.
74. Gregori S, Giarratana N, Smiroldo S i wsp. 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002; 51: 1367-1374.
75. Mattner F, Smiroldo S, Galbiati F i wsp. Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur J Immunol 2000; 30: 498-508.
76. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 2004; 229: 1136-1142.
77. Auer DP, Schumann EM, Kumpfel T i wsp. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000; 47: 276-277
78. Wuthrich R, Rieder HP. The seasonal incidence of multiple sclerosis in Switzerland. Eur Neurol 1970; 3: 257-264.
79. Munger KL, Zhang SM, O.Reilly E i wsp. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62: 60-66.
80. Merlino LA, Curtis J, Mikuls TR i wsp. Iowa Women.s Health Study. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women.s Health Study. Arthritis Rheum 2004; 50: 72-77.
81. Hypponen E, Laara E, Reunanen A i wsp. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358: 1500-1503.
82. Froicu M, Weaver V, Wynn T i wsp. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol 2003; 17: 2386-2392.
83. Fukazawa T, Yabe I, Kikuchi S i wsp. Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. J Neurol Sci 1999; 166: 47-52.
84. Gough A, Sambrook P, Devlin J i wsp. Effect of vitamin D receptor gene alleles on bone loss in early rheumatoid arthritis. J Rheumatol 1998; 25: 864-868.
85. Guja C, Marshall S, Welsh K i wsp. The study of CTLA-4 and vitamin D receptor polymorphisms in the Romanian type 1 diabetes population. J Cell Mol Med 2002; 6: 75-81.
86. Ramos-Lopez E, Kurylowicz A, Bednarczuk T i wsp. Vitamin D Receptor Polymorphisms are Associated with Graves. Disease in German and Polish But not in Serbian Patients. Thyroid 2005; 15: 1125-1130.
87. Morimoto S, Kumahara Y. A patient with psoriasis cured by 1alpha-hydroxyvitamin D3. Med J Osaka Univ 1985; 35: 51-54.
88. Ashcroft DM, Po AL, Williams HC i wsp. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000; 320: 963-967.
89. Takahashi H, Ibe M, Kinouchi M i wsp. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 2003; 31: 21-28.
90. Kang S, Yi S, Griffiths CE i wsp. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol 1998; 138: 77-83.
91. Kelman A, Lane NE. The management of secondary osteoporosis. Best Pract Res Clin Rheumatol 2005; 19: 1021-1037.
92. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 2006; 92: 39-48.
93. Ovesen L, Andersen R, Jakobsen J. Geographical differences in vitamin D status, with particular reference to European countries. Proc Nutr Soc 2003; 62: 813-821.
94. Andersen R, Molgaard C, Skovgaard LT i wsp. Teenage girls and elderly women living in northern Europe have low winter vitamin D status. Eur J Clin Nutr 2005; 59: 533-541.
95. Webb AR. Who, what, where and when influences on cutaneous vitamin D synthesis. Prog Biophys Mol Biol 2006; 92: 17-26.
96. Lamberg-Allardt C. Vitamin D in foods and as SUPPL.ements. Prog Biophys Mol Biol 2006; 92: 33-38.
97. Trang HM, Cole DE, Rubin LA i wsp. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 1998; 68: 854-858.
98. Vieth R, Kimball S, Hu A i wsp. Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients. Nutr J 2004; 3: 8.
99. Holick MF. Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr Opin Endocrinol Diabetes 2002; 9: 87-9-8.